From the Laboratory to the Clinic: AACR Grantee Focuses on Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the bone marrow and the blood that develops in either...
Author:
Karen Honey, PhD
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the bone marrow and the blood that develops in either...
The past month has seen the U.S. Food and Drug Administration (FDA) expand the use of four anticancer therapeutics,...
In the midst of the dog days of summer, the U.S. Food and Drug Administration (FDA) has provided good...
During the early part of summer 2018, the U.S. Food and Drug Administration (FDA) has approved several new anticancer...
This week marks the fourth anniversary of Cancer Research Catalyst, the official blog of the American Association for Cancer...
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab...
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...